Ammon H P, Wahl M A
Department of Pharmacology, Eberhard-Karls-Universität Tübingen, Federal Republic of Germany.
Planta Med. 1991 Feb;57(1):1-7. doi: 10.1055/s-2006-960004.
The data reviewed indicate that extracts of Curcuma longa exhibit anti-inflammatory activity after parenteral application in standard animal models used for testing anti-inflammatory activity. It turned out that curcumin and the volatile oil are at least in part responsible for this action. It appears that when given orally, curcumin is far less active than after i.p. administration. This may be due to poor absorption, as discussed. Data on histamine-induced ulcers are controversial, and studies on the secretory activity (HCl, pepsinogen) are still lacking. In vitro, curcumin exhibited antispasmodic activity. Since there was a protective effect of extracts of Curcuma longa on the liver and a stimulation of bile secretion in animals, Curcuma longa has been advocated for use in liver disorders. Evidence for an effect on liver disease in humans is not yet available. From the facts that after oral application only traces of curcumin were found in the blood and that, on the other hand, most of the curcumin is excreted via the faeces it may be concluded that curcumin is absorbed poorly by the gastrointestinal tract and/or underlies presystemic transformation. Systemic effects therefore seem to be questionable after oral application except that they occur at very low concentrations of curcumin. This does not exclude a local action in the gastrointestinal tract.
所审查的数据表明,在用于测试抗炎活性的标准动物模型中,姜黄提取物经肠胃外给药后具有抗炎活性。结果表明,姜黄素和挥发油至少部分地促成了这一作用。似乎口服时,姜黄素的活性远低于腹腔注射给药后。如前所述,这可能是由于吸收不佳所致。关于组胺诱导溃疡的数据存在争议,而且关于分泌活性(盐酸、胃蛋白酶原)的研究仍然缺乏。在体外,姜黄素表现出解痉活性。由于姜黄提取物对动物肝脏有保护作用并能刺激胆汁分泌,因此有人主张将姜黄用于治疗肝脏疾病。目前尚无关于其对人类肝脏疾病有疗效的证据。从口服后血液中仅发现微量姜黄素以及另一方面大部分姜黄素经粪便排出这一事实可以推断,姜黄素在胃肠道的吸收很差和/或发生了首过转化。因此,口服给药后全身效应似乎存疑,除非在极低浓度的姜黄素情况下才会出现。这并不排除其在胃肠道的局部作用。